CD95L/FasL and its receptor CD95 (APO-1/Fas)

The Cytokine Handbook

Volumn , Issue , 2003, Pages 885-911

  Peter, Marcus E ^a   Barnhart, Bryan C ^a   Algeciras Schimnich, Alicia ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 4143091918     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012689663-3/50042-9     Document Type: Chapter

References (343)

1. Accornero P., Radrizzani M., Delia D., et al. Differential susceptibility of HIV-GP120-sensitized apoptosis in CD4+ T-cell clones with different T-helper phenotypes: role of CD95/CD95L interactions. Blood 1997, 89:558-569.
2. Adachi M., Watanabe-Fukunaga R., Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc. Natl Acad. Sci. USA 1993, 90:1756-1760.
3. Adachi M., Suematsu S., Kondo T., et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat. Genet. 1995, 11:294-300.
4. Alam A., Cohen L.Y., Aouad S., et al. Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells. J. Exp. Med. 1999, 190:1879-1890.
5. Alderson M.R., Armitage R.J., Maraskovsky E., et al. Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med. 1993, 178:2231-2235.
6. Algeciras A., Dockrell D.H., Lynch D.H., et al. CD4 regulates susceptibility to Fas ligand- and tumor necrosis factor-mediated apoptosis. J. Exp. Med. 1998, 187:711-720.
7. Algeciras-Schimnich A., Griffith T.S., Lynch D.H., et al. Cell cycle-dependent regulation of FLIP levels and susceptibility to Fas-mediated apoptosis. J. Immunol. 1999, 162:5205-5211.
8. Algeciras-Schimnich A., Shen L., Barnhart B.C., et al. Molecular ordering of the initial signaling events of CD95. Mol. Cell Biol. 2002, 22:207-220.
9. Allen R.D., Marshall J.D., Roths J.B., et al. Differences defined by bone marrow transplantation suggest that lpr and gld are mutations of genes encoding an interacting pair of molecules. J. Exp. Med. 1990, 172:1367-1375.
10. Allison J., Georgiou H.M., Strasser A., et al. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl Acad. Sci. USA 1997, 94:3943-3947.
11. Andrikoula M., Tsatsoulis A. The role of Fasmediated apoptosis in thyroid disease. Eur. J. Endocrinol. 2001, 144:561-568.
12. Aoki K., Kurooka M., Chen J.J., et al. Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity. Nat. Immunol. 2001, 2:333-337.
13. Aragane Y., Kulms D., Metze D., et al. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of tis ligand CD95L. J. Cell Biol. 1998, 140:171-182.
14. Badley A.D., Dockrell D., Simpson M., et al. Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J. Exp. Med. 1997, 185:55-64.
15. Bansil S., Holtz C.R., Cook S.D., et al. Serum sAPO-1/Fas levels in multiple sclerosis. Acta Neurol. Scand. 1997, 95:208-210.
16. Bellgrau D., Gold D., Selawry H., et al. A role for CD95 ligand in preventing graft rejection. Nature 1995, 377:630-632.
17. Beltinger C., Kurz E., Bohler T., et al. CD95 (APO-1/Fas) mutations in childhood T-lineage accute lymphoblastic leukemia. Blood 1998, 91:3943-3951.
18. Beltinger C., Fulda S., Kammertoens T., et al. Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc. Natl Acad. Sci. USA 1999, 96:8699-8704.
19. Bennett M., Macdonald K., Chan S.W., et al. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 1998, 282:290-293.
20. Bennett M.W., O'Connell J., O'Sullivan G.C., et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 1998, 160:5669-5675.
21. Berke G. The CTL's kiss of death. Cell 1995, 81:9-12.
22. Berndt C., Mopps B., Angermuller S., et al. CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4(+) T cells. Proc. Natl Acad. Sci. USA 1998, 95:12556-12561.
23. Bertin J., Armstrong R.C., Ottilie S., et al. Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc. Natl Acad. Sci. USA 1997, 94:1172-1176.
24. Bissonnette R.P., McGahon A., Mahboubi A., et al. Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hybridomas. J. Exp. Med. 1994, 180:2413-2418.
25. Black R.A., Rauch C.T., Kozlosky C.J. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997, 385:729-733.
26. Blott E.J., Bossi G., Clark R., et al. Fas ligand is targeted to secretory lysosomes via a proline-rich domain in its cytoplasmic tail. J. Cell Sci. 2001, 114:2405-2416.
27. Boehme S.A., Lenardo M.J. Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. Eur. J. Immunol. 1993, 23:1552-1560.
28. Boldin M.P., Goncharov T.M., Goltsev Y.V., et al. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell 1996, 85:803-815.
29. Bonetti B., Pohl J., Gao Y.L., et al. Cell death during autoimmune demyelination: effector but not target cells are eliminated by apoptosis. J. Immunol. 1997, 159:5733-5741.
30. Brunner T., Mogil R.J., LaFace D., et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995, 373:441-444.
31. Brunner T., Kasibhatla S., Pinkoski M.J., et al. Expression of Fas ligand in activated T cells is regulated by c-Myc. J. Biol. Chem. 2000, 275:9767-9772.
32. Butler L.M., Hewett P.J., Butler W.J., et al. Down-regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement. Br. J. Cancer 1998, 77:1454-1459.
33. Cascino I., Fiucci G., Papoff G., et al. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol. 1995, 154:2706-2713.
34. Castro J.E., Listman J.A., Jacobson B.A., et al. Fas modulation of apoptosis during negative selection of thymocytes. Immunity 1996, 5:617-627.
35. Chan F.K., Chen A., Winoto A. Thymic expression of the transcription factor Nur77 rescues the T cell but not the B cell abnormality of gld/gld mice. J. Immunol. 1998, 161:4252-4256.
36. Chan F.K., Chun H.J., Zheng L., et al. A domain in TNF receptors that mediates ligand independent receptor assembly and signaling. Science 2000, 288:2351-2354.
37. Chan H., Bartos D.P., Owen-Schaub L.B. Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-P65 recruitment. Mol. Cell. Biol. 1999, 19:2098-2108.
38. Chang D.W., Xing Z., Pan Y., et al. c-FLIP-L is a dual function regulator for caspase 8 activation and CD95 (APO-1/Fas-mediated apoptosis). EMBO J. 2002, 21:3704-3714.
39. Chinnaiyan A.M., Tepper C., Lou L., et al. FADD/MORT1 is a common mediator of Fas/APO-1-and tumor necrosis factor-induced apoptosis. J. Biol. Chem. 1996, 271:4961-4965.
40. chaudhary P.M., Eby M.T., Jasmin A., et al. Activation of the NFκB pathway by caspase 8 and its homiologs. Oncogene 2000, 19:4451-4460.
41. Chen J.J., Sun Y., Nabel G.J. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998, 282:1714-1717.
42. Cheng J., Zhou T., Liu C., et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994, 263:1759-1762.
43. Cheng L.E., Chan F.K., Cado D., et al. Functional redundancy of the Nur77 and Nor-1 orphan steroid receptors in T-cell apoptosis. EMBO J. 1997, 16:1865-1875.
44. Chow W.A., Fang J.J., Yee J.K. The IFN regulatory factor family participates in regulation of Fas ligand gene expression in T cells. J. Immunol. 2000, 164:3512-3518.
45. Chung C.S., Yang S., Song G.Y., et al. Inhibition of Fas signaling prevents hepatic injury and improves organ blood flow during sepsis. Surgery 2001, 130:339-345.
46. Ciusani E., Frigerio S., Gelati M., et al. Soluble Fas (Apo-1) levels in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 1998, 82:5-12.
47. Combadiere B., Reis e Sousa C., Trageser C., et al. Differential TCR signaling regulates apoptosis and immunopathology during antigen responses in vivo. Immunity 1998, 9:305-313.
48. Comi C., Leone M., Bonissoni S., et al. Defective T cell fas function in patients with multiple sclerosis. Neurology 2000, 55:921-927.
49. Cremesti A., Paris F., Grassme H., et al. Ceramide enables fas to cap and kill. J. Biol. Chem. 2001, 276:23954-23961.
50. Critchfield J.M., Racke M.K., Zuniga-Pflucker J.C., et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994, 263:1139-1143.
51. Cui H., el-Khatib M., Sherr D.H., et al. Characterization of lpr-derived T cell hybridomas: Fas-deficient hybridomas are deathless, growth-arrested, and cytotoxic upon activation. Cell Immunol. 1996, 167:302-312.
52. Dao T., Huleatt J.W., Hingorani R. Specific resistance of T cells to CD95-induced apoptosis during S phase of the cell cycle. J. Immunol. 1997, 159:4261-4267.
53. Davis I.J., Lau L.F. Endocrine and neurogenic regulation of the orphan nuclear receptors Nur77 and Nurr-1 in the adrenal glands. Mol. Cell. Biol. 1994, 14:3469-3483.
54. Desbarats J., Duke R.C., Newell M.K. Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. Nat. Med. 1998, 4:1377-1382.
55. Dhein J., Walczak H., Baumler C., et al. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995, 373:438-441.
56. Dinkel A., Aicher W.K., Haas C., et al. Transcription factor Egr-1 activity down-regulates Fas and CD23 expression in B cells. J. Immunol. 1997, 159:2678-2684.
57. Dittel B.N., Merchant R.M., Janeway C.A. Evidence for Fas-dependent and Fas-independent mechanisms in the pathogenesis of experimental autoimmune encephalomyelitis. J. Immunol. 1999, 162:6392-6400.
58. Djerbi M., Screpanti V., Catrina A.I., et al. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med. 1999, 190:1025-1032.
59. Dowling P., Shang G., Raval S., et al. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J. Exp. Med. 1996, 184:1513-1518.
60. Drappa J., Vaishnaw A.K., Sullivan K.E., et al. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N. Engl. J. Med. 1996, 335:1643-1649.
61. D'Souza S.D., Bonetti B., Balasingam V., et al. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J. Exp. Med. 1996, 184:2361-2370.
62. Du C., Fang M., Li Y., et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42.
63. Dzialo-Hatton R., Milbrandt J., Hockett R.D., et al. Differential expression of Fas ligand in Th1 and Th2 cells is regulated by early growth response gene and NF-AT family members. J. Immunol. 2001, 166:4534-4542.
64. Earnshaw W.C., Martins L.M., Kaufmann S.H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem. 1999, 68:383-424.
65. Eichhorst S.T., Muller M., Li-Weber M., et al. A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol. Cell. Biol. 2000, 20:7826-7837.
66. Ellaurie M., Calvelli T.A., Rubinstein A. Human immunodeficiency virus (HIV) circulating immune complexes in infected children. AIDS Res. Hum. Retroviruses 1990, 6:1437-1441.
67. Elsing A., Burgert H.G. The adenovirus E3/10.4K-14.5K proteins down-modulate the apoptosis receptor Fas/Apo-1 by inducing its internalization. Proc. Natl Acad. Sci. USA 1998, 95:10072-10077.
68. Feijoó E., Subira D., Fernandez-Guerrero M., et al. Anti-CD4 activity in circulating immune complexes in HIV-infected patients. Int. Arch. Allergy Immunol. 1995, 106:366-371.
69. Finkel T.H., Tudor-Williams G., Banda N.K., et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV-and SIV-infected lymph nodes. Nat. Med. 1995, 1:129-134.
70. Fisher G.H., Rosenberg F.J., Straus S.E., et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995, 81:935-946.
71. Fournel S., Genestier L., Robinet E., et al. Human T cells require IL-2 but not G1/S transition to acquire susceptibility to Fas-mediated apoptosis. J. Immunol. 1996, 157:4309-4315.
72. French L.E., Hahne M., Viard I., et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell. Biol. 1996, 133:335-343.
73. Galle P.R., Hofmann W.J., Walczak H., et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 1995, 182:1223-1230.
74. Garrone P., Neidhardt E.M., Garcia E., et al. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J. Exp. Med. 1995, 182:1265-1273.
75. Gandhi R.T., Chen B.K., Straus S.E., et al. HIV-1 directly kills CD4+ T cells by a Fas-independent mechanism. J. Exp. Med. 1998, 187:1113-1122.
76. Gillette-Ferguson I., Sidman C.L. A specific intercellular pathway of apoptotic cell death is defective in the mature peripheral T cells of autoimmune lpr and gld mice. Eur. J. Immunol. 1994, 24:1181-1185.
77. Giordano C., Stassi G., De Maria R., et al. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 1997, 275:960-963.
78. Goltsev Y.V., Kovalenko A.V., Arnold E., et al. CASH, a novel caspase homologue with death effector domains. J. Biol. Chem. 1997, 272:19641-19644.
79. Gougeon M.L., Montagnier L. Apoptosis in AIDS. Science 1993, 260:1269-1270.
80. Grassme H., Jekle A., Riehle A., et al. CD95 signaling via ceramide-rich membrane rafts. J. Biol. Chem. 2001, 276:20589-20596.
81. Grell M., Douni E., Wajant H., et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995, 83:793-802.
82. Griffith T.S., Ferguson T.A. The role of FasL induced apoptosis in immune privilege. Immunol. Today 1997, 18:240-244.
83. Griffith T.S., Brunner T., Fletcher S.M., et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995, 270:1189-1192.
84. Griffith T.S., Chin W.A., Jackson G.C., et al. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 1998, 161:2833-2840.
85. Hahne M., Lowin B., Peitsch M., et al. Interaction of peptides derived from the Fas ligand with the Fyn-SH3 domain. FEBS Lett. 1995, 373:265-268.
86. Hahne M., Rimoldi D., Schroter M., et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996, 274:1363-1366.
87. Han D.K., Chaudhary P.M., Wright M.E., et al. MRIT, a novel death-effector domain-containing protein, interacts with caspases and BclXL and initiates cell death. Proc. Natl Acad. Sci. USA 1997, 94:11333-11338.
88. Harwood F.G., Kasibhatla S., Petak I., et al. Regulation of FasL by NF-kappaB and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells. J. Biol. Chem. 2000, 275:10023-10029.
89. Hayashi N., Mita E. Fas system and apoptosis in viral hepatitis. J. Gastroenterol. Hepatol. 1997, 12:S223-S226.
90. Hegde R., Srinivasula S.M., Zhang Z., et al. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts IAP-caspase interaction. J. Biol. Chem. 2002, 277:432-438.
91. Hennino A., Berard M., Krammer P.H., et al. FLICE-inhibitory protein is a key regulator of germinal center B cell apoptosis. J. Exp. Med. 2001, 193:447-458.
92. Herron L.R., Eisenberg R.A., Roper E., et al. Selection of the T cell receptor repertoire in Lpr mice. J. Immunol. 1993, 151:3450-3459.
93. Hohlbaum A.M., Moe S., Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J. Exp. Med. 2000, 191:1209-1220.
94. Holler N., Zaru R., Micheau O., et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 2000, 1:489-495.
95. Hornung F., Zheng L., Lenardo M.J. Maintenance of clonotype specificity in CD95/Apo-1/Fas-mediated apoptosis of mature T lymphocytes. J. Immunol. 1997, 159:3816-3822.
96. Hosaka N., Oyaizu N., Kaplan M.H., et al. Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons. J. Infect. Dis. 1998, 178:1030-1039.
97. Hsu S.C., Gavrilin M.A., Lee H.H., et al. NF-kappa B-dependent Fas ligand expression. Eur. J. Immunol. 1999, 29:2948-2956.
98. Hsu S.C., Gavrillin M.A., Tsai M.H., et al. p38 mitogen-activated protein kinase is involved in Fas ligand expression. J. Biol. Chem. 1999, 274:25769-25776.
99. Hu S., Vincenz C., Buller M., et al. A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis. J. Biol. Chem. 1997, 272:9621-9624.
100. Hu S., Vincenz C., Ni J., et al. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J. Biol. Chem. 1997, 272:17255-17257.
101. Hu W.H., Johnson H., Shu H.B. Activation of NF-kappaB by FADD, Casper, and caspase-8. J. Biol. Chem. 2000, 275:10838-10844.
102. Huang W-X., Huang M.P., Gomes M.A., et al. Apoptosis mediators fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS. Neurology 2000, 55:928-934.
103. Hueber A.O., Zornig M., Lyon D., et al. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science 1997, 278:1305-1309.
104. Imai Y., Kimura T., Murakami A., et al. The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis. Nature 1999, 398:777-785.
105. Inaba M., Kurasawa K., Mamura M., et al. Primed T cells are more resistant to Fas-mediated activation-induced cell death than naive T cells. J. Immunol. 1999, 163:1315-1320.
106. Inazawa J., Itoh N., Abe T., et al. Assignment of the human Fas antigen gene (Fas) to 10q24.1. Genomics 1992, 14:821-822.
107. Inohara N., Koseki T., Hu Y., et al. CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis. Proc. Natl Acad. Sci. USA 1997, 94:10717-10722.
108. Inoue A., Koh C.S., Sakai T., et al. Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. J. Neuroimmunol. 1997, 75:141-146.
109. Irisarri M., Plumas J., Bonnefoix T., et al. Resistance to CD95-mediated apoptosis through constitutive c-FLIP expression in a non-Hodgkin's lymphoma B cell line. Leukemia 2000, 14:2149-2158.
110. Irmler M., Thome M., Hahne M., et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388:190-195.
111. Ishida M., Miyazaki K., Kumagai K., Rikimaru M. Neocarzinostatine, an antitumor antibiotic of high molecular weight isolation, physical properties and biological activities. J. Antibiot. 1965, 18:68.
112. Ishigatsubo Y., Steinberg A.D., Klinman D.M. Autoantibody production is associated with polyclonal B cell activation in autoimmune mice which express the lpr or gld genes. Eur. J. Immunol. 1988, 18:1089-1093.
113. Itai T., Tanaka M., Nagata S. Processing of tumor necrosis factor by the membrane-bound TNF-alpha-converting enzyme, but not its truncated soluble form. Eur. J. Biochem. 2001, 268:2074-2082.
114. Itoh N., Yonehara S., Ishii A., et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66:233-243.
115. Itoh N., Imagawa A., Hanafusa T., et al. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J. Exp. Med. 1997, 186:613-618.
116. Ivanov V.N., Ronai Z. p38 protects human melanoma cells from UV-induced apoptosis through down-regulation of NF-kappaB activity and Fas expression. Oncogene 2000, 19:3003-3012.
117. Ivanov V.N., Bhoumik A., Krasilnikov M., et al. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol. Cell 2001, 7:517-528.
118. Jacotot E., Ravagnan L., Loeffler M., et al. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J. Exp. Med. 2000, 191:33-46.
119. Jenkins M., Keir M., McCune J.M. A membrane-bound Fas decoy receptor expressed by human thymocytes. J. Biol. Chem. 2000, 275:7988-7993.
120. Ju S.T., Panka D.J., Cui H., et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995, 373:444-448.
121. Kamihira S., Yamada Y., Hirakata Y., et al. Aberrant expression of caspase cascade regulatory genes in adult T-cell leukaemia: survivin is an important determinant for prognosis. Br. J. Haematol. 2001, 114:63-69.
122. Kang S.M., Schneider D.B., Lin Z., et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 1997, 3:738-743.
123. Karas M., Zaks T.Z., Liu J.L., et al. T cell receptor-induced activation and apoptosis in cycling human T cells occur throughout the cell cycle. Mol. Biol. Cell 1999, 10:4441-4450.
124. Kasibhatla S., Brunner T., Genestier L., et al. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol. Cell 1998, 1:543-551.
125. Kataoka T., Budd R.C., Holler N., et al. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr. Biol. 2000, 10:640-648.
126. Katsikis P.D., Wunderlich E.S., Smith C.A., et al. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J. Exp. Med. 1995, 181:2029-2036.
127. Kayagaki N., Kawasaki A., Ebata T., et al. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 1995, 182:1777-1783.
128. Keane M.M., Ettenberg S.A., Lowrey G.A., et al. Fas expression and function in normal and malignant breast cell lines. Cancer Res. 1996, 56:4791-4798.
129. Kennedy N.J., Kataoka T., Tschopp J., et al. Caspase activation is required for T cell proliferation. J. Exp. Med. 1999, 190:1891-1896.
130. Kim S., Kim K.A., Hwang D.Y., et al. Inhibition of autoimmune diabetes by Fas ligand: the paradox is solved. J. Immunol. 2000, 164:2931-2936.
131. Kirchhoff S., Muller W.W., Krueger A., et al. TCR-mediated up-regulation of c-FLIPshort correlates with resistance toward CD95-mediated apoptosis by blocking death-inducing signaling complex activity. J. Immunol. 2000, 165:6293-6300.
132. Kirchhoff S., Muller W.W., Li-Weber M., et al. Up-regulation of c-FLIPshort and reduction of activation-induced cell death in CD28-costimulated human T cells. Eur. J. Immunol. 2000, 30:2765-2774.
133. Kischkel F.C., Hellbardt S., Behrmann I., et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995, 14:5579-5588.
134. Kischkel F.C., Lawrence D.A., Tinel A., et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J. Biol. Chem. 2001, 276:46639-46646.
135. Kishimoto H., Surh C.D., Sprent J. A role for Fas in negative selection of thymocytes in vivo. J. Exp. Med. 1998, 187:1427-1438.
136. Klas C., Debatin K.M., Jonker R.R., et al. Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol. 1993, 5:625-630.
137. Kneitz B., Herrmann T., Yonehara S., et al. Normal clonal expansion but impaired Fas-mediated cell death and anergy induction in interleukin-2-deficient mice. Eur. J. Immunol. 1995, 25:2572-2577.
138. Kobayashi S., Hirano T., Kakinuma M., et al. Transcriptional repression and differential splicing of Fas mRNA by early transposon (ETn) insertion in autoimmune lpr mice. Biochem. Biophys. Res. Commun. 1993, 191:617-624.
139. Kondo T., Suda T., Fukuyama H., et al. Essential roles of the Fas ligand in the development of hepatitis. Nat. Med. 1997, 3:409-413.
140. Koonin E.V., Aravind L., Hofmann K., et al. Apoptosis. Searching for FLASH domains. Nature 1999, 401:662.
141. Korsmeyer S.J., Wei M.C., Saito M. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 2000, 7:1166-1173.
142. Krueger A., Schmitz I., Baumann S., et al. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J. Biol. Chem. 2001, 276:20633-20640.
143. Lacronique V., Mignon A., Fabre M., et al. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat. Med. 1996, 2:80-86.
144. Lagresle C., Mondier E.P., Bella C., et al. Concurrent engagement of CD40 and the antigen receptor protects naive and memory human B cells from APO-1/Fas-mediated apoptosis. J. Exp. Med. 1996, 183:1377-1388.
145. Lam K.P., Rajewsky K. Rapid elimination of mature autoreactive B cells demonstrated by Cre-induced change in B cell antigen receptor specificity in vivo. Proc. Natl Acad. Sci. USA 1998, 95:13171-13175.
146. Lam K.P., Kuhn R., Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997, 90:1073-1083.
147. Landowski T.H., Qu N., Buyuksal I., et al. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997, 90:4266-4270.
148. Lasham A., Lindridge E., Rudert F., et al. Regulation of the human fas promoter by YB-1, Puralpha and AP-1 transcription factors. Gene 2000, 252:1-13.
149. Latinis K.M., Norian L.A., Eliason S.L., et al. Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cells. J. Biol. Chem. 1997, 272:31427-31434.
150. Lau H.T., Yu M., Fontana A., et al. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996, 273:109-112.
151. Lee M.P., Feinberg A.P. Genomic imprinting of a human apoptosis gene homologue, TSSC3. Cancer Res. 1998, 58:1052-1056.
152. Lee S.L., Wesselschmidt R.L., Linette G.P. Unimpaired thymic and peripheral T cell death in mice lacking the nuclear receptor NGFI-B (Nur77). Science 1995, 269:532-535.
153. Lee S.H., Shin M.S., Park W.S., et al. Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res. 1999, 59:3068-3072.
154. Lee S.H., Shin M.S., Park W.S., et al. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 1999, 18:3754-3760.
155. Leithauser F., Dhein J., Mechtersheimer G., et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest. 1993, 69:415-429.
156. Lenardo M.J. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 1991, 353:858-861.
157. Li C.J., Friedman D.J., Wang C., et al. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 1995, 268:429-431.
158. Li H., Zhu H., Xu CJ., et al. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94:491-501.
159. Li H., Leo C., Zhu J., et al. Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Mol. Cell. Biol. 2000, 20:1784-1796.
160. Li L.Y., Luo X., Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001, 412:95-99.
161. Li P., Nijhawan D., Budihardjo I., et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91:479-489.
162. Li X.K., Okuyama T., Tamura A., et al. Prolonged survival of rat liver allografts transfected with Fas ligand-expressing plasmid. Transplantation 1998, 66:1416-1423.
163. Li Y., Kanki H., Hachiya T., et al. Negative regulation of Fas-mediated apoptosis by FAP-1 in human cancer cells. Int. J. Cancer 2000, 87:473-479.
164. Lichter P., Walczak H., Weitz S., et al. The human APO-1 (APT) antigen maps to 10q23, a region that is syngtenic with mouse chromosome 19. Genomics 1992, 14:179-180.
165. Lindsten T., Ross A.J., King A., et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol. Cell 2000, 6:1389-1399.
166. Liu Z.G., Smith S.W., McLaughlin K.A., et al. Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate-early gene nur77. Nature 1994, 367:281-284.
167. Li-Weber M., Laur O., Krammer P.H. Novel Egr/NF-AT composite sites mediate activation of the CD95 (APO-1/Fas) ligand promoter in response to T cell stimulation. Eur. J. Immunol. 1999, 29:3017-3027.
168. Li-Weber M., Laur O., Dern K., et al. T cell activation-induced and HIV tat-enhanced CD95(APO-1/Fas) ligand transcription involves NF-kappaB. Eur. J. Immunol. 2000, 30:661-670.
169. Luo X., Budihardjo I., Zou H., et al. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998, 94:481-490.
170. Lynch D.H., Watson M.L., Alderson M.R., et al. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1994, 1:131-136.
171. Macchi B., Matteucci C., Nocentini U., et al. Impaired apoptosis in mitogen-stimulated lymphocytes of patients with multiple sclerosis. Neuroreport 1999, 10:399-402.
172. Mandik L., Nguyen K.A., Erikson J. Fas receptor expression on B-lineage cells. Eur. J. Immunol. 1995, 25:3148-3154.
173. Mariani S.M., Matiba B., Baumler C., et al. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur. J. Immunol. 1995, 25:2303-2307.
174. Martin R., McFarland H.F., McFarlin D.E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 1992, 10:153-187.
175. Martins L.M., Iaccarino I., Tenev T., et al. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a Reaper-like motif. J. Biol. Chem. 2002, 277:439-444.
176. Matsui K., Fine A., Zhu B., et al. Identification of two NF-kappa B sites in mouse CD95 ligand (Fas ligand) promoter: functional analysis in T cell hybridoma. J. Immunol. 1998, 161:3469-3473.
177. Matsuno H., Yudoh K., Watanabe Y., et al. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. J. Rheumatol. 2001, 28:22-28.
178. Matsuzawa A., Moriyama T., Kaneko T., et al. A new allele of the lpr locus, lprcg, that complements the gld gene in induction of lymphadenopathy in the mouse. J. Exp. Med. 1990, 171:519-531.
179. McCloskey T.W., Oyaizu N., Kaplan M., et al. Expression of the Fas antigen in patients infected with human immunodeficiency virus. Cytometry 1995, 22:111-114.
180. McGahon A.J., Nishioka W.K., Martin S.J., et al. regulation of the Fas apoptotic cell death pathway by Abl. J. Biol. Chem. 1995, 270:22625-22631.
181. Medema J.P., de Jong J., van Hall T., et al. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 1999, 190:1033-1038.
182. Meyaard L., Otto S.A., Jonker R.R., et al. Programmed death of T cells in HIV-1 infection. Science 1992, 257:217-219.
183. Mitra D., Steiner M., Lynch D.H., et al. HIV-1 upregulates Fas ligand expression in CD4+ T cells in vitro and in vivo: association with Fas-mediated apoptosis and modulation by aurintricarboxylic acid. Immunology 1996, 87:581-585.
184. Mitsiades N., Poulaki V., Kotoula V., et al. Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis. J. Clin. Endocrinol. Metab. 1998, 83:2199-2203.
185. Mitsiades N., Yu W.H., Poulaki V., et al. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 2001, 61:577-581.
186. Mittelstadt P.R., Ashwell J.D. Cyclosporin A-sensitive transcription factor Egr-3 regulates Fas ligand expression. Mol. Cell. Biol. 1998, 18:3744-3751.
187. Miwa K., Asano M., Horai R., et al. Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat. Med. 1998, 4:1287-1292.
188. Moers C., Warskulat U., Muschen M., et al. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin. Int. J. Cancer. 1999, 80:564-572.
189. Moller P., Koretz K., Leithauser F., et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer 1994, 57:371-377.
190. Moriwaki M., Itoh N., Miyagawa J., et al. Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with recent-onset Type I diabetes mellitus. Diabetologia 1999, 42:1332-1340.
191. Moss M.L., Jin S.L., Milla M.E., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997, 385:733-736.
192. Mountz J.D., Wu J., Cheng J., et al. Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum. 1994, 37:1415-1420.
193. Muller M., Strand S., Hug H., et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 1997, 99:403-413.
194. Muller M., Wilder S., Bannasch D., et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 1998, 188:2033-2045.
195. Munsch D., Watanabe-Fukunaga R., Bourdon J.C., et al. Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis. J. Biol. Chem. 2000, 275:3867-3872.
196. Muschen M., Moers C., Warskulat U., et al. CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology 2000, 99:69-77.
197. Muschen M., Re D., Jungnickel B., et al. Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. J. Exp. Med. 2000, 192:1833-1840.
198. Muzio M., Chinnaiyan A.M., Kischkel F.C., et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996, 85:817-827.
199. Newton K., Harris A.W., Bath M.L., et al. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J. 1998, 17:706-718.
200. Ni R., Tomita Y., Matsuda K., et al. Fas-mediated apoptosis in primary cultured mouse hepatocytes. Exp. Cell Res. 1994, 215:332-337.
201. Nishimura Y., Hirabayashi Y., Matsuzaki Y., et al. In vivo analysis of Fas antigen-mediated apoptosis: effects of agonistic anti-mouse Fas mAb on thymus, spleen and liver. Int. Immunol. 1997, 9:307-316.
202. Norian L.A., Latinis K.M., Koretzky G.A. A newly identified response element in the CD95 ligand promoter contributes to optimal inducibility in activated T lymphocytes. J. Immunol. 1998, 161:1078-1082.
203. O'Connell J., O'Sullivan G.C., Collins J.K., et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 1996, 184:1075-1082.
204. O'Connell J., Bennett M.W., O'Sullivan G.C., et al. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J. Pathol. 1998, 186:240-246.
205. Oehm A., Behrmann I., Falk W., et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J. Biol. Chem. 1992, 267:10709-10715.
206. Ogasawara J., Watanabe-Fukunaga R., Adachi M., et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993, 364:806-809.
207. Oh S.K., Cruikshank W.W., Raina J., et al. Identification of HIV-1 envelope glycoprotein in the serum of AIDS and ARC patients. J. Acquir. Immune Defic. Syndr. 1992, 5:251-256.
208. Okada K., Komuta K., Hashimoto S., et al. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin. Cancer Res. 2000, 6:3560-3564.
209. O'Reilly L.A., Huang D.C., Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J. 1996, 15:6979-6990.
210. Ottonello L., Tortolina G., Amelotti M., et al. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J. Immunol. 1999, 162:3601-3606.
211. Owen-Schaub L.B., Yonehara S., Crump W.L., et al. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell. Immunol. 1992, 140:197-205.
212. Owen-Schaub L., Chan H., Cusack J.C., et al. Fas and Fas ligand interactions in malignant disease. Int. J. Oncol. 2000, 17:5-12.
213. Oyaizu N., McCloskey T.W., Than S., et al. Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-gamma and tumor necrosis factor-alpha secretion. Blood 1994, 84:2622-2631.
214. Oyaizu N., Adachi Y., Hashimoto F., et al. Monocytes express Fas ligand upon CD4 cross-linking and induce CD4+ T cells apoptosis: a possible mechanism of bystander cell death in HIV infection. J. Immunol. 1997, 158:2456-2463.
215. Papoff G., Hausler P., Eramo A., et al. Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J. Biol. Chem. 1999, 274:38241-38250.
216. Peduto Eberl L., Guillou L., Saraga E., et al. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas. Int. J. Cancer 1999, 81:772-778.
217. Peter M.E., Krammer P.H. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr. Opin. Immunol. 1998, 10:545-551.
218. Peter M.E., Hellbardt S., Schwartz-Albiez R., et al. Cell surface sialylation plays a role in modulating sensitivity towards APO-1-mediated apoptotic cell death. Cell Death Differ. 1995, 2:163-171.
219. Peter M.E., Heufelder A., Hengartner M.O. Advances in apoptosis research. Proc. Natl Acad. Sci. USA 1997, 94:12736-12737.
220. Peter M.E., Scaffidi C., Medema J.P., et al. The death receptors. Results Probl. Cell. Differ. 1999, 23:25-63.
221. Pianko S., Patella S., Ostapowicz G., et al. Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. J. Viral. Hepat. 2001, 8:406-413.
222. Pitti R.M., Marsters S.A., Lawrence D.A., et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998, 396:699-703.
223. Powell W.C., Fingleton B., Wilson C.L., et al. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr. Biol. 1999, 9:1441-1447.
224. Qian N., Frank D., O'Keefe D., et al. The IPL gene on chromosome 11p15.5 is imprinted in humans and mice and is similar to TDAG51, implicated in Fas expression and apoptosis. Hum. Mol. Genet. 1997, 6:2021-2029.
225. Que F.G., Phan V.A., Phan V.H., et al. Cholangio-carcinomas express Fas ligand and disable the Fas receptor. Hepatology 1999, 30:1398-1404.
226. Radvanyi L.G., Mills G.B., Miller R.G. Religation of the T cell receptor after primary activation of mature T cells inhibits proliferation and induces apoptotic cell death. J. Immunol. 1993, 150:5704-5715.
227. Ramsdell R., Seaman M.S., Miller R.E., et al. gld/gld mice are unable to express a functional ligand for Fas. Eur. J. Immunol. 1994, 24:928-933.
228. Rathmell J.C., Townsend S.E., Xu J.C., et al. Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 1996, 87:319-329.
229. Reap E.A., Leslie D., Abrahams M., et al. Apoptosis abnormalities of splenic lymphocytes in autoimmune lpr and gld mice. J. Immunol. 1995, 154:936-943.
230. Refaeli Y., Van Parijs L., London C.A., et al. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 1998, 8:615-623.
231. Rensing-Ehl A., Frei K., Flury R., et al. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur. J. Immunol. 1995, 25:2253-2258.
232. Restifo N.P. Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat. Med. 2000, 6:493-495.
233. Rieux-Laucat F., Le Deist C., Hivroz I.A., et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995, 268:1347-1349.
234. Rivera-Walsh I., Cvijic M.E., Xiao G., et al. The NF-kappa B signaling pathway is not required for Fas ligand gene induction but mediates protection from activation-induced cell death. J. Biol. Chem. 2000, 275:25222-25230.
235. Rodriguez I., Matsuura K., Khatib K., et al. A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J. Exp. Med. 1996, 83:1031-1036.
236. Roth W., Isenmann S., Nakamura M., et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res. 2001, 61:2759-2765.
237. Roths J.B., Murphy E.D., Eicher E.M. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J. Exp. Med. 1984, 159:1-20.
238. Rothstein T.L., Wang J.K., Panka D.J., et al. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 1995, 374:163-165.
239. Russell J.H. Activation-induced death of mature T cells in the regulation of immune responses. Curr. Opin. Immunol. 1995, 7:382-388.
240. Ryu B.K., Lee M.G., Chi S.G., et al. Increased expression of cFLIP(L) in colonic adenocarcinoma. J. Pathol. 2001, 194:15-19.
241. Sabelko K.A., Kelly K.A., Nahm M.H., et al. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J. Immunol. 1997, 159:3096-3099.
242. Sabelko-Downes K.A., Russell J.H., Cross A.H. Role of Fas-FasL interactions in the pathogenesis and regulation of autoimmune demyelinating disease. J. Neuroimmunol. 1999, 100:42-52.
243. Sakai T., Inoue A., Koh C.S., et al. Serum levels of apoptosis-related molecules in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. J. Interferon Cytokine Res. 1999, 19:999-1004.
244. Salvesen G.S., Dixit V.M. Caspase activation: the induced-proximity model. Proc. Natl Acad. Sci. USA 1999, 96:10964-10967.
245. Sato T., Irie S., Kitada S., et al. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995, 268:411-415.
246. Scaffidi C., Medema J.P., Krammer P.H., et al. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J. Biol. Chem. 1997, 272:26953-26958.
247. Scaffidi C., Fulda S., Srinivasan A., et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998, 17:1675-1687.
248. Scaffidi C., Schmitz I., Krammer P.H., et al. The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. 1999, 274:1541-1548.
249. Schattner E.J., Elkon K.B., Yoo D.H., et al. CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J. Exp. Med. 1995, 182:1557-1565.
250. Schneider P., Bodmer J.L., Holler N., et al. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J. Biol. Chem. 1997, 272:18827-18833.
251. Schulze-Osthoff K., Ferrari D., Los M., et al. Apoptosis signaling by death receptors. Eur. J. Biochem. 1998, 254:439-459.
252. Seino K., Kayagaki N., Okumura K., et al. Antitumor effect of locally produced CD95 ligand. Nat. Med. 1997, 3:165-170.
253. Seino K., Iwabuchi K., Kayagaki N., et al. Chemotactic activity of soluble Fas ligand against phagocytes. J. Immunol. 1998, 161:4484-4488.
254. Semra Y.K., Seidi O.A., Sharief M.K. Overexpression of the apoptosis inhibitor FLIP in T cells correlates with disease activity in multiple sclerosis. J. Neuroimmunol. 2001, 113:268-274.
255. Sharief M.K. Increased cellular expression of the caspase inhibitor FLIP in intrathecal lymphocytes from patients with multiple sclerosis. J. Neuroimmunol. 2000, 111:203-209.
256. Shi Y.F., Sahai B.M., Green D.R. Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes. Nature 1989, 339:625-626.
257. Shi Y.F., Szalay M.G., Paskar L., et al. Activation-induced cell death in T cell hybridomas is due to apoptosis. Morphologic aspects and DNA fragmentation. J. Immunol. 1990, 144:3326-3333.
258. Shi Y., Glynn J.M., Guilbert L.J., et al. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 1992, 257:212-214.
259. Shin M.S., Park W.S., Kim S.Y., et al. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am. J. Pathol. 1999, 154:1785-1791.
260. Shu H.B., Halpin D.R., Goeddel D.V. Casper is a FADD- and caspase-related inducer of apoptosis. Immunity 1997, 6:751-763.
261. Siegel R.M., Chan F.K., Chun H.J., et al. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat. Immunol. 2000, 1:469-474.
262. Siegel R.M., Frederiksen J.K., Zacharias D.A., et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000, 288:2354-2357.
263. Silvestris F., Cafforio P., Camarda G., et al. Functional Fas-ligand expression on T cells from HIV-1-infected patients is unrelated to CD4+ lymphopenia. Int. J. Clin. Lab. Res. 1998, 28:215-225.
264. Singer G.G., Abbas A.K. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994, 1:365-371.
265. Srinivasula S.M., Ahmad M., Ottilie S., et al. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J. Biol. Chem. 1997, 272:18542-18545.
266. Stanger B.Z., Leder P., Lee T.H., et al. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 1995, 81:513-523.
267. Stassi G., Todaro M., Bucchieri F., et al. Fas/Fas ligand-driven T cell apoptosis as a consequence of ineffective thyroid immunoprivilege in Hashimoto's thyroiditis. J. Immunol. 1999, 162:263-267.
268. Stegh A.H., Herrmann H., Lampel S., et al. Identification of the cytolinker plectin as a major early in vivo substrate for caspase-8 during CD95 and TNF-receptor mediated apoptosis. Mol. Cell. Biol. 2000, 20:5665-5679.
269. Stegh A.H., Barnhart B., Volkland J., et al. Inactivation of caspase-8 on mitochondria of Bcl-xL expressing MCF7-Fas cells: role for the BAR protein. J. Biol. Chem. 2002, 277:4351-4360.
270. Strack P.R., Frey M.W., Rizzo C.J., et al. Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2. Proc. Natl Acad. Sci. USA 1996, 93:9571-9576.
271. Strand S., Hofmann W.J., Hug H., et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion?. Nat. Med. 1996, 2:1361-1366.
272. Strand S., Hofmann W.J., Grambihler A., et al. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nat. Med. 1998, 4:588-593.
273. Strasser A., Harris A.W., Huang D.C., et al. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J. 1995, 14:6136-6147.
274. Straus S.E., Jaffe E.S., Puck J.M., et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001, 98:194-200.
275. Stuart P.M., Griffith T.S., Usui N., et al. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Invest. 1997, 99:396-402.
276. Su X., Hu Q., Kristan J.M., et al. Significant role for Fas in the pathogenesis of autoimmune diabetes. J. Immunol. 2000, 164:2523-2532.
277. Suda T., Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J. Exp. Med. 1994, 179:873-879.
278. Suda T., Takahashi T., Golstein P., et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993, 75:1169-1178.
279. Suda T., Tanaka M., Miwa K. Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. J. Immunol. 1996, 157:3918-3924.
280. Suda T., Hashimoto H., Tanaka M., et al. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 1997, 186:2045-2050.
281. Suvannavejh G.C., Dal Canto M.C., Matis L.A., et al. Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 2000, 105:223-231.
282. Suzuki I., Fink P.J. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J. Exp. Med. 1998, 187:123-128.
283. Suzuki Y., Imai Y., Nakayama H., et al. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol. Cell. 2001, 8:613-621.
284. Swenson K.M., Ke B., Wang T., et al. Fas ligand gene transfer to renal allografts in rats: effects on allograft survival. Transplantation 1998, 65:155-160.
285. Takahashi S., Maecker H.T., Levy R. DNA fragmentation and cell death mediated by T cell antigen receptor/CD3 complex on a leukemia T cell line. Eur. J. Immunol. 1989, 19:1911-1919.
286. Takahashi T., Tanaka M., Brannan C.I., et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994, 76:969-976.
287. Takahashi T., Tanaka M., Inazawa J., et al. Human Fas ligand: gene structure, chromosomal location and species specificity. Int. Immunol. 1994, 6:1567-1574.
288. Takahashi Y., Ohta H., Takemori T. Fas is required for clonal selection in germinal centers and the subsequent establishment of the memory B cell repertoire. Immunity 2001, 14:181-192.
289. Tanaka M., Suda T., Takahashi T., et al. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J. 1995, 14:1129-1135.
290. Tanaka M., Suda T., Yatomi T., et al. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J. Immunol. 1997, 158:2303-2309.
291. Tanaka M., Itai T., Adachi M., et al. Downregulation of Fas ligand by shedding. Nat. Med. 1998, 4:31-36.
292. Tantaglia L.A., Ayres T.M., Wong G.H., Goeddel D.V. A novel domain within the 55 KD TNF receptor signals cell death. Cell 1993, 74:845-853.
293. Thome M., Schneider P., Hofmann K., et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997, 386:517-521.
294. Tollefson A.E., Hermiston T.W., Lichtenstein D.L., et al. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature 1998, 392:726-730.
295. Torii S., Egan D.A., Evans R.A., et al. Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs). EMBO J. 1999, 18:6037-6049.
296. Trauth B.C., Klas C., Peters A.M., et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989, 245:301-305.
297. Tsutsui H., Kayagaki N., Kuida K., et al. Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity 1999, 11:359-367.
298. Ucker D.S., Ashwell J.D., Nickas G. Activation-driven T cell death. I. Requirements for de novo transcription and translation and association with genome fragmentation. J. Immunol. 1989, 143:3461-3469.
299. Ucker D.S., Meyers J., Obermiller P.S. Activation-driven T cell death. II. quantitative differences alone distinguish stimuli triggering nontransformed T cell proliferation or death. J. Immunol. 1992, 149:1583-1592.
300. van Eijk M., Medema J.P., de Groot C. Cellular Fas-associated death domain-like IL-1-converting enzyme-inhibitory protein protects germinal center B cells from apoptosis during germinal center reactions. J. Immunol. 2001, 166:6473-6476.
301. Van Parijs L., Abbas A.K. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998, 280:243-248.
302. Van Parijs L., Ibraghimov A., Abbas A.K. The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Immunity 1996, 4:321-328.
303. Van Parijs L., Refaeli Y., Lord J.D., et al. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity 1999, 11:281-288.
304. Verhagen A.M., Ekert P.G., Pakusch M., et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102:43-53.
305. Verhagen A.M., Silke J., Ekert P.G. HtrA2 promotes cell death through its serine protease activity and its ability to antagonise inhibitor of apoptosis proteins. J. Biol. Chem. 2002, 277:445-454.
306. Vlahakis S.R., Algeciras-Schimnich A., Bou G., et al. Chemokine-receptor activation by env determines the mechanism of death in HIV-infected and uninfected T lymphocytes. J. Clin. Invest. 2001, 107:207-215.
307. Walczak H., Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res. 2000, 256:58-66.
308. Walczak H., Miller R.E., Ariail K., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 1999, 5:157-163.
309. Waldner H., Sobel R.A., Howard E., et al. Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. J. Immunol. 1997, 159:3100-3103.
310. Walker P.R., Saas P., Dietrich P.Y. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J. Immunol. 1997, 158:4521-4524.
311. Wallach D., Varfolomeev E.E., Malinin N.L., et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 1999, 17:331-367.
312. Walters D.E., Prakash I., Desai N. Active conformations of neotame and other high-potency sweeteners. J. Med. Chem. 2000, 43:1242-1245.
313. Wang J., Zheng L., Lobito A., et al. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 1999, 98:47-58.
314. Wang J., Lobito A.A., Shen F., et al. Inhibition of Fas-mediated apoptosis by the B cell antigen receptor through c-FLIP. Eur. J. Immunol. 2000, 30:155-163.
315. Wang J., Chun H.J., Wong W., et al. Caspase-10 is an initiator caspase in death receptor signaling. Proc. Natl Acad. Sci. USA 2001, 98:13884-13888.
316. Wang R., Zhang L., Yin D., et al. Protein kinase C regulates Fas (CD95/APO-1) expression. J. Immunol. 1998, 161:2201-2207.
317. Wang Z.G., Ruggero D., Ronchetti S., et al. PML is essential for multiple apoptotic pathways. Nat. Genet. 1998, 20:266-272.
318. Watanabe-Fukunaga R., Brannan C.I., Copeland N.G., et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992, 356:314-317.
319. Wei M.C., Zong W.X., Cheng E.H., et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292:727-730.
320. Wesselborg S., Janssen O., Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J. Immunol. 1993, 150:4338-4345.
321. Westendorp M.O., Frank R., Ochsenbauer C., et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995, 375:497-500.
322. Westendorp M.O., Shatrov V.A., Schulze-Osthoff K., et al. HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. EMBO J. 1995, 14:546-554.
323. Woronicz J.D., Calnan B., Ngo V., et al. Requirement for the orphan steroid receptor Nur77 in apoptosis of T-cell hybridomas. Nature 1994, 367:277-281.
324. Wu J., Zhou T., He J., et al. Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. J. Exp. Med. 1993, 178:461-468.
325. Wu J., Wilson J., He J., et al. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J. Clin. Invest. 1996, 98:1107-1113.
326. Xerri L., Carbuccia N., Parc P., et al. Frequent expression of FAS/APO-1 in Hodgkin's disease and anaplastic large cell lymphomas. Histopathology 1995, 27:235-241.
327. Xiao S., Matsui K., Fine A., et al. FasL promoter activation by IL-2 through SP1 and NFAT but not Egr-2 and Egr-3. Eur. J. Immunol. 1999, 29:3456-3465.
328. Yanagisawa J., Takahashi M., Kanki H., et al. The molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis. J. Biol. Chem. 1997, 272:8539-8545.
329. Yang X., Khosravi-Far R., Chang H.Y., et al. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 1997, 89:1067-1076.
330. Yeh W.C., Itie A., Elia A.J., et al. Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 2000, 12:633-642.
331. Yin X-M., Wang K., Gross A., et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999, 400:886-891.
332. Yonehara S., Ishii A., Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 1989, 169:1747-1756.
333. Yoong K.F., Afford S.C., Randhawa S., et al. Fas/Fas ligand interaction in human colorectal hepatic metastases: a mechanism of hepatocyte destruction to facilitate local tumor invasion. Am. J. Pathol. 1999, 154:693-703.
334. Zang Y.C., Kozovska M.M., Hong J., et al. Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Eur. J. Immunol. 1999, 29:1692-1700.
335. Zauli G., Gibellini D., Secchiero P., et al. Human immunodeficiency virus type 1 Nef protein sensitizes CD4(+) T lymphoid cells to apoptosis via functional upregulation of the CD95/CD95 ligand pathway. Blood 1999, 93:1000-1010.
336. Zhang J., Markovic-Plese S., Lacet B., et al. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 1994, 179:973-984.
337. Zhang J., Cado D., Chen A., et al. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 1998, 392:296-300.
338. Zhong S., Salomoni P., Ronchetti S., et al. Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. J. Exp. Med. 2000, 191:631-640.
339. Zhou B.B., Li H., Yuan J., et al. Caspase-dependent activation of cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells. Proc. Natl Acad. Sci. USA 1998, 95:6785-6790.
340. Zhou Q., Snipas S., Orth K., et al. Target protease specificity of the viral serpin CrmA. Analysis of five caspases. J. Biol. Chem. 1997, 272:7797-7800.
341. Zhou T., Cheng J., Yang P., et al. Inhibition of Nur77/Nurr1 leads to inefficient clonal deletion of self-reactive T cells. J. Exp. Med. 1996, 183:1879-1892.
342. Zhou Y.W., Komada Y., Inaba H. Down-regulation of Fas-associated phosphatase-1 (FAP-1) in interleukin-2-activated T cells. Cell. Immunol. 1998, 186:103-110.
343. Zipp F., Weller M., Calabresi P.A., et al. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Ann. Neurol. 1998, 43:116-120.